Medi­gene, RXi strike re­search deal to im­prove TCRs; Bris­tol-My­ers pays PsiOxus $15M mile­stone for tri­al-ready on­colyt­ic virus

→ A pre­clin­i­cal re­search col­lab­o­ra­tion has brought Marl­bor­ough, MA-based RXi Phar­ma­ceu­ti­cals and Ger­many’s Medi­gene to­geth­er in hopes of im­prov­ing Medi­gene’s adaop­tive T-cell can­cer ther­a­pies. The plan is to in­te­grate tiny RXi’s self-de­liv­er­ing RNAi tech­nol­o­gy in­to Medi­gene’s process to pro­duce re­cep­tor-mod­i­fied T cells, which can in turn be di­rect­ed against a pre­de­fined tu­mor anti­gen. “The use of our im­muno-on­col­o­gy sd-rxR­NA com­pounds with their re­cep­tor-mod­i­fied T cells could po­ten­tial­ly cre­ate a next gen­er­a­tion of very pow­er­ful adop­tive cell ther­a­pies against se­ri­ous can­cers that cur­rent­ly are dif­fi­cult to tar­get,” said RXi CEO Geert Cauwen­bergh in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER